Protagonist Therapeutics, Inc. $PTGX Shares Sold by American Century Companies Inc.

American Century Companies Inc. lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 26.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 600,047 shares of the company’s stock after selling 213,948 shares during the period. American Century Companies Inc. owned 0.96% of Protagonist Therapeutics worth $39,861,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Salomon & Ludwin LLC purchased a new position in Protagonist Therapeutics during the third quarter worth about $29,000. EverSource Wealth Advisors LLC grew its stake in shares of Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after buying an additional 314 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in shares of Protagonist Therapeutics in the 3rd quarter valued at $62,000. Osaic Holdings Inc. lifted its stake in Protagonist Therapeutics by 79.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after acquiring an additional 525 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Protagonist Therapeutics by 11.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after acquiring an additional 146 shares in the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Protagonist Therapeutics

In related news, Director William D. Waddill sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $654,796. This represents a 71.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Lewis T. Williams sold 18,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the completion of the transaction, the director directly owned 7,825 shares of the company’s stock, valued at approximately $644,936.50. This represents a 69.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 203,167 shares of company stock worth $16,889,199 in the last quarter. 4.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. TD Cowen raised their price target on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Barclays boosted their price target on shares of Protagonist Therapeutics from $108.00 to $113.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. The Goldman Sachs Group increased their price target on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a research note on Tuesday. Citigroup raised their price objective on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, Jefferies Financial Group boosted their price objective on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Protagonist Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $99.00.

Protagonist Therapeutics Stock Up 0.7%

Shares of PTGX opened at $92.09 on Friday. Protagonist Therapeutics, Inc. has a fifty-two week low of $37.94 and a fifty-two week high of $96.54. The company’s fifty day moving average is $84.70 and its two-hundred day moving average is $78.15. The firm has a market cap of $5.88 billion, a PE ratio of -44.92 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. The firm had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. As a group, equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.